SAN DIEGO, July 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the "Class Period"), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit.  Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with vi ...

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI’s top ...

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Class Action Lawsuit Details - The lawsuit is titled Shouse v. Tempus AI, Inc., and it allows purchasers of Tempus AI common stock between August 6, 2024, and May 27, 2025, to seek appointment as lead plaintiff by August 12, 2025 [1]. - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins [3]. - Allegations include that the joint venture with SoftBank Group Corporation appeared to involve "round-tripping" capital, raising concerns about revenue legitimacy [3]. Group 2: Financial and Operational Concerns - The lawsuit highlights that the acquisition of Ambry Genetics Corporation involved aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - It is alleged that AstraZeneca PLC reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement [3]. - A research report from Spruce Point Capital Management raised red flags regarding Tempus AI's management and financial reporting, resulting in a stock price drop of over 19% on May 28, 2025 [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Tempus AI common stock during the Class Period to seek lead plaintiff status, representing the interests of the class [5]. - The lead plaintiff can select a law firm of their choice to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].